NYSE:CGC (Canada) Also trade in: Canada Germany UK

Canopy Growth Corp

$ 44.61 0 (0%)
Volume: 2,875,419 Avg Vol (1m): 5,848,473
Market Cap $: 15.30 Bil Enterprise Value $: 12.38 Bil
P/E (TTM): 0.00 P/B: 2.62
Earnings Power Value 4.09
Net Current Asset Value 9.09
Tangible Book 12.33
Projected FCF 9.15
Median P/S Value 31.82
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 6.21
Cash-To-Debt ranked higher than
69.50% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
CGC: 6.21
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.47, Med: 10000, Max: 10000
Current: 6.21
0.47
10000
Equity-to-Asset 0.84
Equity-to-Asset ranked higher than
77.16% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
CGC: 0.84
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.54, Med: 0.9, Max: 1
Current: 0.84
0.54
1
Debt-to-Equity 0.11
Debt-to-Equity ranked higher than
97.15% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
CGC: 0.11
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.03, Max: 0.56
Current: 0.11
0
0.56
Debt-to-EBITDA -1.94
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
CGC: -1.94
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -15.89, Med: -0.2, Max: 4.29
Current: -1.94
-15.89
4.29
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.64
DISTRESS
GREY
SAFE
Beneish M-Score 9.92
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -25.38%
WACC 32.13%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -285.68
Operating Margin ranked lower than
85.39% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
CGC: -285.68
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -2700, Med: -420, Max: -10.38
Current: -285.68
-2700
-10.38
Net Margin % -265.24
Net Margin ranked lower than
84.66% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
CGC: -265.24
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2700, Med: -420, Max: -18.85
Current: -265.24
-2700
-18.85
ROE % -16.96
ROE ranked lower than
70.19% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
CGC: -16.96
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -80.59, Med: -4.73, Max: -1.97
Current: -16.96
-80.59
-1.97
ROA % -12.65
ROA ranked lower than
69.35% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
CGC: -12.65
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -67.48, Med: -4.38, Max: -1.78
Current: -12.65
-67.48
-1.78
ROC (Joel Greenblatt) % -75.56
ROC (Joel Greenblatt) ranked lower than
72.98% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
CGC: -75.56
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -89.11, Med: -18.46, Max: -3.11
Current: -75.56
-89.11
-3.11
3-Year Total Revenue Growth Rate 308.20
3-Year Revenue Growth Rate ranked higher than
98.84% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
CGC: 126.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 126.2, Max: 337.5
Current: 126.2
0
337.5
3-Year Total EBITDA Growth Rate -99.30
3-Year EBITDA Growth Rate ranked lower than
79.97% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
CGC: -10.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -10.2, Max: 57.5
Current: -10.2
0
57.5
3-Year EPS w/o NRI Growth Rate -10.10
3-Year EPS w/o NRI Growth Rate ranked lower than
75.41% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
CGC: -10.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -128.9, Med: -10.1, Max: 13.4
Current: -10.1
-128.9
13.4

» CGC's 30-Y Financials

Financials (Next Earnings Date: 2019-08-15)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:CGC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 3741
Compare XTAE:TEVA TSE:4523 TSE:4507 NSE:SUNPHARMA NAS:MYL SZSE:000538 NYSE:ELAN SZSE:300122 SHSE:600196 XPAR:IPN SHSE:600332 TSX:ACB HKSE:03320 TSE:4506 XSWX:VIFN OCSE:LUN TSX:BHC SHSE:600518 TSE:4581 SZSE:000963
Traded in other countries WEED.Canada 11L1.Germany 0UO9.UK
Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp through its subsidiaries is the licensed producer of medical marijuana in Canada. The company grows, produces and sells medical marijuana. It operates diverse brands and variety supported by over half million square feet of indoor and greenhouse marijuana production. It sells medical marijuana under various brand names including Tweed, Bedrocan, and Mettrum. A majority of the revenue is derived from the sale of medical marijuana by Tweed and Bedrocan in Canada.

Ratios

Current vs industry vs history
PB Ratio 2.62
PB Ratio ranked lower than
81.56% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
CGC: 2.62
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.02, Med: 2.22, Max: 10.56
Current: 2.62
0.02
10.56
PS Ratio 97.94
PS Ratio ranked lower than
94.71% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
CGC: 97.94
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 7.5, Med: 69.86, Max: 3370
Current: 97.94
7.5
3370
EV-to-EBIT -37.61
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
CGC: -37.61
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -290.6, Med: -10.45, Max: 359.6
Current: -37.61
-290.6
359.6
EV-to-EBITDA -40.74
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
CGC: -40.74
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -2523.9, Med: -1.5, Max: 2031.2
Current: -40.74
-2523.9
2031.2
EV-to-Revenue 107.44
EV-to-Revenue ranked lower than
93.21% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
CGC: 107.44
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -7601, Med: 28.7, Max: 562.9
Current: 107.44
-7601
562.9
Current Ratio 17.85
Current Ratio ranked higher than
77.89% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
CGC: 17.85
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.64, Med: 12.8, Max: 516
Current: 17.85
0.64
516
Quick Ratio 17.22
Quick Ratio ranked higher than
75.79% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
CGC: 17.22
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.51, Med: 9.02, Max: 516
Current: 17.22
0.51
516
Days Inventory 334.71
Days Inventory ranked lower than
99.47% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
CGC: 334.71
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 277.12, Med: 3923.21, Max: 10528.75
Current: 334.71
277.12
10528.75
Days Sales Outstanding 224.69
Days Sales Outstanding ranked higher than
89.09% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
CGC: 224.69
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 25.56, Med: 29.68, Max: 58.29
Current: 224.69
25.56
58.29
Days Payable 556.49
Days Payable ranked higher than
96.04% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
CGC: 556.49
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 354.55, Med: 1478.97, Max: 4487.19
Current: 556.49
354.55
4487.19

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -69.90
3-Year Share Buyback Rate ranked lower than
91.94% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
CGC: -69.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -380, Med: -177.6, Max: 8.6
Current: -69.9
-380
8.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.62
Price-to-Tangible-Book ranked lower than
85.85% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
CGC: 3.62
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.02, Med: 2.46, Max: 34.73
Current: 3.62
0.02
34.73
Price-to-Projected-FCF 4.87
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
96.79% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
CGC: 4.87
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.97, Med: 7.51, Max: 18.49
Current: 4.87
2.97
18.49
Price-to-Median-PS-Value 1.41
Price-to-Median-PS-Value ranked lower than
72.68% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
CGC: 1.41
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.11, Med: 0.89, Max: 10.71
Current: 1.41
0.11
10.71
Earnings Yield (Joel Greenblatt) % -2.66
Earnings Yield (Greenblatt) ranked lower than
69.43% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
CGC: -2.66
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -2824.9, Med: -0.7, Max: 138.1
Current: -2.66
-2824.9
138.1

More Statistics

Revenue (TTM) (Mil) $ 117.09
EPS (TTM) $ -2.02
Beta 3.87
Volatility % 118.35
52-Week Range $ 24.21 - 59.25
Shares Outstanding (Mil) 342.98

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N